Prevention of lymphocyte apoptosis in septic mice with cancer increases mortality

Lymphocyte apoptosis is thought to have a major role in the pathophysiology of sepsis. However, there is a disconnect between animal models of sepsis and patients with the disease, because the former use subjects that were healthy prior to the onset of infection while most patients have underlying comorbidities. The purpose of this study was to determine whether lymphocyte apoptosis prevention is effective in preventing mortality in septic mice with preexisting cancer. Mice with lymphocyte Bcl-2 overexpression (Bcl-2-Ig) and wild type (WT) mice were injected with a transplantable pancreatic adenocarcinoma cell line. Three weeks later, after development of palpable tumors, all animals received an intratracheal injection of Pseudomonas aeruginosa. Despite having decreased sepsis-induced T and B lymphocyte apoptosis, Bcl-2-Ig mice had markedly increased mortality compared with WT mice following P. aeruginosa pneumonia (85 versus 44% 7-d mortality; p = 0.004). The worsened survival in Bcl-2-Ig mice was associated with increases in Th1 cytokines TNF-α and IFN-γ in bronchoalveolar lavage fluid and decreased production of the Th2 cytokine IL-10 in stimulated splenocytes. There were no differences in tumor size or pulmonary pathology between Bcl-2-Ig and WT mice. To verify that the mortality difference was not specific to Bcl-2 overexpression, similar experiments were performed in Bim(-/-) mice. Septic Bim(-/-) mice with cancer also had increased mortality compared with septic WT mice with cancer. These data demonstrate that, despite overwhelming evidence that prevention of lymphocyte apoptosis is beneficial in septic hosts without comorbidities, the same strategy worsens survival in mice with cancer that are given pneumonia.

The optimal tumor response assessment in patients with HCC after treatment of TACE

215

Background: WHO or RECIST has been considered as suboptimal methods for tumor response assessment in HCC, especially receiving locoregional therapies. Recently, new modified methods having concept of viable tumor has been proposed. Herein we compared the efficacy to assess response and to predict prognosis between WHO, RECIST, EASL, mRECIST in HCC patients receiving TACE.

Methods: We retrospectively reviewed 141 HCC patients who were newly diagnosed and received TACE between August 2005 and November 2006. Among them, 98 patients who were available for assessing treatment response were analyzed at 1 month after 2nd TACE. We evaluated intermethod aggreement between methods and assessed the efficacy predicting time to progression (TTP) and overall survival (OS).

Results: The results of tumor responses (number of CR/ PR/ SD/ PD) by WHO/ RECIST/ EASL/ mRECIST were 1/ 14/ 74/ 9, 1/ 12/ 77/ 8, 34/ 34/ 25/ 5, 34/ 28/ 31/ 5, respectively. The κvalue of intermethod agreement for EASL vs WHO, EASL vs RECIST, mRECIST vs WHO, and mRECIST vs RECIST was 0.102, 0.088, 0.112 and 0.122, respectively. The κvalue for WHO vs RECIST and EASL vs mRECIST was 0.759 and 0.883 (p=0.00). Hazard ratios for TTP in responders compared with nonresponders were 0.313 (95% CI; 0.19-0.52, p=0.00) for EASL and 0.335 (95% CI; 0.21-0.54, p=0.00) for mRECIST. Hazard ratios for survival in responders compared with nonresponders were 0.208 (95% CI; 0.12-0.37, p=0.00) for EASL and 0.269 (95% CI; 0.15-0.48, p=0.00) for mRECIST. In the univariate analysis, tumor size, infiltrative type, PVT, EASL responder, and mRECIST responder were significant risk factors for survival. Multivariate analysis showed EASL responder (HR 0.165, 95% CI 0.056-0.486, p=0.001) and infiltrative type (HR 4.504, 95% CI 1.579-12.848, p=0.005) were independent predictable factors for survival.

Conclusions: The recent proposed methods showed different characteristics from preexisting methods in assessing treatment response and furthermore, responder by EASL method was independent predictor for survival in HCC patients receiving TACE. EASL method should be applied as response assessment method for HCC patients receiving TACE.

No significant financial relationships to disclose.

Whitening effect of alpha-bisabolol in Asian women subjects

SYNOPSIS

Although skin pigmentation, which results from the production and distribution of melanin in the epidermis, is the major physiological defence against solar irradiation, hyperpigmentation is a common and distressing problem caused by various inflammatory skin disorders, such as eczema, allergic contact dermatitis and irritant contact dermatitis. We evaluated the effects of a preparation containing alpha-bisabolol on pigmented skin of a group of subjects. The effectiveness of the active compound, alpha-bisabolol, in a base-cream preparation for the treatment of pigmented skin was tested on 28 female subjects as follows: the cream was applied once a day to the back for 8 weeks. These same women also applied a vehicle control cream to the pigmented skin. The results were evaluated by clinical and biophysical test methods. After 8 weeks of treatment of the alpha-bisabolol-containing cream, there was significant lightening effect in the pigmented skin for the majority of the subjects who tested the cream.

Promotion of stem cell proliferation by vegetable peptone

OBJECTIVES

Technical limitations and evolution of therapeutic applications for cell culture-derived products have accelerated elimination of animal-derived constituents from such products to minimize inadvertent introduction of microbial contaminants, such as fungi, bacteria or viruses. The study described here was conducted to investigate the proliferative effect of vegetable peptone on adult stem cells in the absence of serum, and its possible mechanisms of action.

MATERIALS AND METHODS

Cell viability and proliferation were determined using the MTT assay and Click-iT EdU flow cytometry, respectively. In addition, changes in expression of cytokine genes were analysed using MILLIPLEX human cytokine enzyme-linked immunosorbent assay kit.

RESULTS

Viability of cord blood-derived mesenchymal stem cells (CB-MSC) and adipose tissue-derived stem cells (ADSC) increased significantly when treated with the peptone. In addition, median value of the group treated with peptone shifted to the right when compared to the untreated control group. Furthermore, quantitative analysis of the cytokines revealed that production of vascular endothelial growth factor (VEGF), transforming growth factor-beta1 (TGF-beta1), and interleukin-6 (IL-6) increased significantly in response to treatment with our vegetable peptone in both CB-MSCs and ADSCs.

CONCLUSIONS

Our findings revealed that the vegetable peptone promotes proliferation of CB-MSCs and ADSCs. In addition, results of this study suggest that induction of stem cell proliferation by vegetable peptone is likely to be related to its induction of VEGF, TGF-beta1, and IL-6 expression.

Expression of EGFR, VEGF, and K-ras mutation as predictors for response of cetuximab in colorectal cancer patients

e15147

Background: Cetuximab has been effective in metastatic colorectal cancer (CRC) patients. EGFR is involved in CRC through its downstream signaling pathways, including RAS and MAKP pathway and angiogenesis. We evaluated the predictive value of EGFR and VEGF expressions and K-ras mutation status in colorectal cancer patients treated with cetuximab in combination with chemotherapy Methods: Our study included 29 CRC patients treated with cetuximab in combination with chemotherapy (20 patients with FOLFIRI and 5 patients with FOLFOX, and 4 patients with monotherapy). Paraffin blocked tumor tissues were analyzed for EGFR and VEGF expression using quantitative real time PCR and K-ras mutation status (codons 12 and 13) using direct sequencing. Results: 12 patients (43%) had a partial response (PR) and 6 patients (21%) with stable disease (SD) and 11 patients (38%) with progressive disease (PD). EGFR expression was not correlated with the response of cetuximab (p=0.60) The median EGFR expression level was 0.30 x 10-3 in PR and 0.25 x 10-3 in SD and 0.26 x 10-3 in PD. High VEGF expression was associated with the response of cetuximab (p=0.03). The mean VEGF expression level was 4.3 x 10-3 in PR and 1.64 x 10-3 in SD and 1.72 x 10-3 in PD. A K-ras mutation was present in 45 % (13/29) and did not significantly correlated with non-response of cetuximab (p=0.05). A K-ras mutation was detected 33% (4/12) in PR and 33% (2/6) in SD and 70 % (7/10) in PD. Conclusions: VEGF expression in tumor may be a potential predictor for the response of cetuximab. But EGFR expression and K-ras mutation status is not significantly correlated with clinical outcome of cetuximab. And a K-ras mutation is found in the response group.

[Table: see text]

[Risk of nanoparticles?]

Nanotechnology is an "emerging industry" and becomes more widely used. As a result human exposure to nanoparticles is inevitable. Exposure to nanoparticles can affect the upper aerodigestive tract, before particles reach lung, stomach and intestine. The effects of this passage depend on particle size, particle concentration, the kind of the particle and the duration of contact. Only few in-vitro-investigations about effects of the exposition of nanoparticles on the mucous cells of oral cavity, nose and nasal sinuses exist. In-vitro-analysis with cells of nasal mucous membrane exposed to nanoparticles showed a release of mediators involved in inflammation and allergy development. Cytotoxic and genotoxic effects could be found for several nanoparticles (e.g. carbon nanotubes) in vitro. Due to different size, structure, chemical and physical properties nanoparticles can not be summarized in a homogenous group; quite the contrary risk evaluation of nanoparticles must be carried out case-related. Today toxicological risks can not be evaluated sufficiently. Biological interactions and tissue permeability of manufactured nanoparticles is a major issue for further investigations. In this report the use and health effects of nanoparticles are overviewed.